Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fulcrum Therapeutics, Inc.FULC · Entity 5969 | Director · See Remarks | January 19, 2022 | January 21, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fulcrum Therapeutics, Inc.
Report date January 19, 2022 · Filed January 21, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.69 · Expires 2032-01-18 | Direct | 340,000 |
Reported balance
After 2022-01-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-19 · Grant · Acquired 340,000 · Balance 340,000 F1: This option was granted on January 19, 2022 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2022, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on January 19, 2022 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2022, subject to continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 19, 2022 Filed Jan 21, 2022 16:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 340,000 | $0.00 Strike: $12.69 | $0.00 |
DisclosureSEC source: 0000899243-22-002879 · doc4.xml · derivative · entry 1 Stuart Bryan · CIK 0001619846 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,000 Underlying: Common Stock · 340,000 shares Expires 2032-01-18 F1 · derivative.exercise_date: This option was granted on January 19, 2022 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2022, subject to continued service. Read SEC document |
| August 11, 2021 Filed Aug 12, 2021 16:20 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionStock Option (right to buy) · Derivative | 28,000 | $0.00 Strike: $7.84 | $0.00 |
DisclosureSEC source: 0000899243-21-032753 · doc4.xml · derivative · entry 6 Stuart Bryan · CIK 0001619846 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,571 Underlying: Common Stock · 28,000 shares Expires 2028-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2020. F2 · derivative.exercise_date: This option was granted on December 18, 2018 and is scheduled to vest 25% on the first anniversary of the vesting commencement date of December 18, 2018. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service. Read SEC document |
| August 11, 2021 Filed Aug 12, 2021 16:20 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | SaleCommon Stock | 28,000 | $23.75 | $665,000.00 |
DisclosureSEC source: 0000899243-21-032753 · doc4.xml · nonDerivative · entry 4 Stuart Bryan · CIK 0001619846 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2020. Read SEC document |
| August 11, 2021 Filed Aug 12, 2021 16:20 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionCommon Stock | 28,000 | $7.84 | $219,520.00 |
DisclosureSEC source: 0000899243-21-032753 · doc4.xml · nonDerivative · entry 3 Stuart Bryan · CIK 0001619846 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2020. Read SEC document |
| August 10, 2021 Filed Aug 12, 2021 16:20 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionStock Option (right to buy) · Derivative | 32,000 | $0.00 Strike: $7.84 | $0.00 |
DisclosureSEC source: 0000899243-21-032753 · doc4.xml · derivative · entry 5 Stuart Bryan · CIK 0001619846 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,571 Underlying: Common Stock · 32,000 shares Expires 2028-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2020. F2 · derivative.exercise_date: This option was granted on December 18, 2018 and is scheduled to vest 25% on the first anniversary of the vesting commencement date of December 18, 2018. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service. Read SEC document |
| August 10, 2021 Filed Aug 12, 2021 16:20 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | SaleCommon Stock | 32,000 | $17.50 | $560,000.00 |
DisclosureSEC source: 0000899243-21-032753 · doc4.xml · nonDerivative · entry 2 Stuart Bryan · CIK 0001619846 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2020. Read SEC document |
| August 10, 2021 Filed Aug 12, 2021 16:20 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionCommon Stock | 32,000 | $7.84 | $250,880.00 |
DisclosureSEC source: 0000899243-21-032753 · doc4.xml · nonDerivative · entry 1 Stuart Bryan · CIK 0001619846 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2020. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 16:30 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 350,000 | $0.00 Strike: $11.78 | $0.00 |
DisclosureSEC source: 0000899243-21-014592 · doc4.xml · derivative · entry 1 Stuart Bryan · CIK 0001619846 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2031-03-30 F1 · derivative.exercise_date: This option was granted on March 31, 2021 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of March 31, 2021, subject to continued service. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 16:30 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 134,376 | $0.00 Strike: $13.09 | $0.00 |
DisclosureSEC source: 0000899243-21-003474 · doc4.xml · derivative · entry 1 Stuart Bryan · CIK 0001619846 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,376 Underlying: Common Stock · 134,376 shares Expires 2031-01-24 F1 · derivative.exercise_date: This option was granted on January 25, 2021 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2021, subject to continued service. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 16:31 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 105,000 | $0.00 Strike: $16.87 | $0.00 |
DisclosureSEC source: 0000899243-20-002041 · doc4.xml · derivative · entry 1 Stuart Bryan · CIK 0001619846 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2030-01-22 F1 · derivative.exercise_date: This option was granted on January 23, 2020 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2020, subject to continued service. Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 17:26 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 28,571 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001104659-19-040966 · a4.xml · derivative · entry 1 Stuart Bryan · CIK 0001619846 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,571 Underlying: Common Stock · 28,571 shares Expires 2029-07-17 F1 · derivative.exercise_date: The option was granted on July 18, 2019. The shares underlying the option are scheduled to vest in equal quarterly installments from July 1, 2019 through June 30, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.